Summary
Becton Dickinson and Company (BDX) filed its 2008 10-K report, detailing its operations as a global medical technology company. The company is structured into three key segments: BD Medical, BD Diagnostics, and BD Biosciences, offering a wide array of products and devices for healthcare institutions, life science researchers, and clinical laboratories. The report highlights BD's commitment to innovation through significant investments in research and development, which are crucial for maintaining its competitive edge in a rapidly evolving medical technology landscape. BD's business is characterized by its diverse product portfolio and global presence, with substantial operations outside the U.S. The company emphasizes safety-engineered devices and diagnostic solutions, particularly in areas like infectious disease testing and cell analysis. However, BD also faces considerable risks, including the impact of current economic conditions, foreign currency fluctuations, intense competition, regulatory scrutiny, and ongoing legal proceedings, particularly antitrust litigation. Investors should note the company's efforts to mitigate these risks through strategic initiatives, product development, and operational efficiency.
Financial Highlights
52 data points| Revenue | $6.90B |
| Cost of Revenue | $3.36B |
| Gross Profit | $3.54B |
| SG&A Expenses | $1.67B |
| Operating Expenses | $5.41B |
| Operating Income | $1.49B |
| Interest Expense | $36.34M |
| Net Income | $1.13B |
| EPS (Basic) | $4.61 |
| EPS (Diluted) | $4.46 |
| Shares Outstanding (Basic) | 244.32M |
| Shares Outstanding (Diluted) | 252.68M |
Key Highlights
- 1BD operates through three main segments: Medical, Diagnostics, and Biosciences, offering a broad range of medical supplies, devices, laboratory equipment, and diagnostic products.
- 2The company made a strategic acquisition of Cytopeia Inc. in May 2008, aiming to advance its capabilities in cell-based research and flow cytometry.
- 3BD maintains a significant global presence, with over half of its fiscal year 2008 revenues derived from international operations, across various regions including Europe, Asia Pacific, and Latin America.
- 4Significant investments in research and development are a core strategy, with approximately $396 million spent in fiscal year 2008 to drive innovation and maintain a competitive advantage.
- 5The company is subject to numerous legal proceedings, including antitrust class action lawsuits and product liability claims, which could impact financial results.
- 6BD is actively managing risks associated with foreign currency exchange rates due to its substantial international revenue base.
- 7The report details BD's extensive network of manufacturing, warehousing, and administrative facilities globally, underscoring its operational scale.